Avant Immunotherapeutics Expands Senior Management Team With Appointment Of Ronald W. Ellis, Ph.D., Senior Vice President, Research And Development

NEEDHAM, Mass.--(BUSINESS WIRE)--Jan. 23, 2006--AVANT Immunotherapeutics (Nasdaq: AVAN) today announced the appointment of Ronald W. Ellis, Ph.D. as Senior Vice President, Research and Development. Dr. Ellis had previously been Senior Vice President, Development, for ID Biomedical Corporation, which was recently acquired by GlaxoSmithKline. He was also General Manager of ID Biomedical’s Northborough, Massachusetts vaccine development and pilot manufacturing facility, which he had started up for a predecessor company in 1998.

MORE ON THIS TOPIC